De Novo Protein Sequencing Technology


Our commitment to pursue the most pioneering, leading-edge proteomic technologies has driven us to add de novo Protein and Antibody Sequencing to our service provision.

“This year we will focus on ensuring a seamless results-driven service and apply our extensive knowledge and experience across a broad range of pioneering proteomic disciplines to provide our customers with world-leading innovative offerings.”

Keiryn L Bennett Ph.D.  Lead Proteomic Scientist

Whether you require the sequence for rare organisms you are researching, or you suspect amino acid substitutions have occurred in your recombinant protein, de novo protein sequencing can be indispensable in furthering your research and quality control processes. At DC Biosciences we are delighted to announce we have partnered with the leading de novo protein sequencing team to offer proteomic services as part of our portfolio.

Through offering the most advanced option for characterising your key reagents with mass spectrometry techniques, our team is ensuring the reliability and predictability of your research.

Protein Sequencing Service

De novo protein sequencing by mass spectrometry allows researchers to resurrect lost hybridomas, re-engineer protein backbones, and recombinantly reproduce key reagents with high consistency. By employing a de novo approach, this technique can sequence directly from the protein of interest, without requiring access to the original hybridoma-producing cell line.

By subjecting the protein to a multi-enzyme digest, the protein is reduced to smaller peptide fragments that can be analysed by LC-MSMS. The resultant spectral data is analysed by a proprietary bioinformatic algorithm that then assembles the full amino acid sequence based on overlapping peptides. The resultant sequence has an average of 30 times coverage for each individual amino acid, resulting in a 100% accurate result.

Specific requirements for protein sequencing projects will be determined on a case-by-case basis, based upon protein purity and size.

Antibody Sequencing Service

The de novo antibody protein sequencing platform offers a mass spectrometry solution that accurately obtains the full amino acid sequence without requiring the cell line or DNA. Requiring only 100 µg of the antibody protein, we can ensure accurate data for any species, any isotype with 100% accuracy and 100% coverage. Within 2-3 weeks we will deliver a detailed report with the heavy and light chain antibody sequences along with any notable observations including sites for any present post translational modifications.

De novo protein sequencing enables you to:

  • Resurrect your lost antibodies.

Recover antibodies that fell victim to lost cell lines, batch variability, and vendor discontinuation by obtaining the protein sequence enabling recombinant synthesis.

  • Secure your antibody supply chain.

As the most widely used reagents in the life sciences, antibodies are subject to both supply and quality issues due to inconsistent quality control protocols. Overcome these challenges with the protein sequence to benefit from a reliable supply with predictable biologic activity.

  • Accelerate your ‘Proof-of-Concept’ studies.

When conducting feasibility studies, the amino acid sequence can enable researchers to engineer various constructs simultaneously, thus enabling a more efficient process for testing optimal combinations against their target. This not only streamlines testing, but also guarantees future reproducibility.

Whatever your protein sequencing needs we are happy to chat through your project and find the best solution for you. Our new de novo protein sequencing service is the latest addition to our comprehensive proteomic offering and further confirms our unrivalled reputation in this key area ensuring we continue to stand out from other providers.

To discuss further please get in touch

Point of View
Related Posts: